FDA approves hepcidin mimetic for PV - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA approves hepcidin mimetic for PV

Phase 3 VERIFY results showed a 77% clinical response rate during weeks 20 to 32.

  • By

  • Kathryn Wighton

  • August 31, 2026

  • 3 min

Share

Objective:

To report the FDA approval of rusfertide (MIMRYLO) for treating erythrocytosis in adults with polycythemia vera.

Approach:
  • Treatment Overview: Rusfertide is a hepcidin mimetic administered weekly via subcutaneous injection, aimed at regulating iron distribution and red blood cell overproduction.
  • Clinical Trial: The approval was supported by the phase 3 VERIFY trial, a randomized, placebo-controlled study involving 293 patients with uncontrolled hematocrit.
Key Findings:
  • 77% of patients receiving rusfertide plus standard of care achieved a clinical response during weeks 20 to 32.
  • Rusfertide treatment resulted in better hematocrit control and reduced need for phlebotomy compared to placebo.
  • Common adverse reactions included injection-site reactions (56%) and anemia (16%).
Limitations:
  • Warnings include new or worsening thrombocytosis, injection-site reactions, and embryo-fetal toxicity.
Sources:

Original Source(s)

FDA approves hepcidin mimetic for PV

  • by Kathryn Wighton

  • August 31, 2026

Related Content

FDA clears targeted cholangiocarcinoma therapy

In the single-arm REFOCUS trial, 46% of patients responded to treatment, with a median response duration of 11.8 months.

Educators weigh how to use AI without losing critical thinking

Greater productivity is not necessarily indicative of greater knowledge.

What happens to clinical skills when AI does the routine work?

“The need to be extra vigilant when you're reviewing something versus doing it from scratch can be a real problem.”